{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:59:56Z","timestamp":1767923996260,"version":"3.49.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1097\/fpc.0000000000000256","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T18:55:31Z","timestamp":1479236131000},"page":"43-50","source":"Crossref","is-referenced-by-count":10,"title":["The plausible association of MTHFR and ADORA2A polymorphisms with nodules in rheumatoid arthritis patients treated with methotrexate"],"prefix":"10.1097","volume":"27","author":[{"given":"Tomas","family":"Soukup","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dosedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Nekvindova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ales","family":"Antonin Kubena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilja","family":"Tacheci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurjen","family":"Duintjer Tebbens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Vlcek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Bradna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Barvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Pavek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-1-20210213","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/annrheumdis-2013-204588","article-title":"Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Gaujoux-Viala","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R3-1-20210213","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R4-1-20210213","first-page":"S179","article-title":"Methotrexate as the \u2018anchor\u2019 drug for the treatment of early rheumatoid arthritis","volume":"21","author":"Pincus","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"R5-1-20210213","doi-asserted-by":"crossref","first-page":"536050","DOI":"10.1155\/2014\/536050","article-title":"Anti-cyclic citrullinated peptide (anti-CCP) and anti-mutated citrullinated vimentin (anti-MCV) relation with extra-articular manifestations in rheumatoid arthritis","volume":"2014","author":"Gonzalez-Lopez","year":"2014","journal-title":"J Immunol Res"},{"key":"R6-1-20210213","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.1780310915","article-title":"Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis","volume":"31","author":"Segal","year":"1988","journal-title":"Arthritis Rheum"},{"key":"R7-1-20210213","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/s10165-006-0522-2","article-title":"Rheumatoid nodulosis during methotrexate therapy in a patient with rheumatoid arthritis","volume":"16","author":"Matsushita","year":"2006","journal-title":"Mod Rheumatol"},{"key":"R8-1-20210213","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF02030360","article-title":"Eruption of nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis","volume":"8","author":"Jeurissen","year":"1989","journal-title":"Clin Rheumatol"},{"key":"R9-1-20210213","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaad.2004.07.023","article-title":"Rheumatoid arthritis: a review of the cutaneous manifestations","volume":"53","author":"Sayah","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R10-1-20210213","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jbspin.2005.01.006","article-title":"Calcaneal osteomyelitis due to fistulization of an ulcerated rheumatoid nodule","volume":"73","author":"Alcaraz","year":"2006","journal-title":"Joint Bone Spine"},{"key":"R11-1-20210213","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s10067-014-2645-8","article-title":"Association of the MTHFR C677T and A1298C polymorphisms with methotrexate toxicity in rheumatoid arthritis: a meta-analysis","volume":"33","author":"Song","year":"2014","journal-title":"Clin Rheumatol"},{"key":"R12-1-20210213","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/RHU.0b013e31816d5ea5","article-title":"A rare case of Enterobacter endocarditis superimposed on a mitral valve rheumatoid nodule","volume":"14","author":"Giladi","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"R13-1-20210213","first-page":"S33","article-title":"Methotrexate pharmacogenetics in rheumatoid arthritis","volume":"28","author":"Brinker","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"R14-1-20210213","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2174\/138920009789375414","article-title":"Polymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising","volume":"10","author":"Gervasini","year":"2009","journal-title":"Curr Drug Metab"},{"key":"R15-1-20210213","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/rheumatology\/ken182","article-title":"Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX","volume":"47","author":"Hider","year":"2008","journal-title":"Rheumatology"},{"key":"R16-1-20210213","first-page":"1308","article-title":"Adenosine a1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis","volume":"40","author":"Merrill","year":"1997","journal-title":"Arthritis Rheum"},{"key":"R17-1-20210213","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"R18-1-20210213","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/art.22640","article-title":"A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis","volume":"56","author":"Wessels","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R19-1-20210213","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9","article-title":"Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration","volume":"43","author":"Anderson","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R20-1-20210213","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"key":"R22-1-20210213","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1017\/S0007114500000751","article-title":"The effect of 677C\u2192T and 1298A\u2192C mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects","volume":"83","author":"Chango","year":"2000","journal-title":"Br J Nutr"},{"key":"R23-1-20210213","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar2994","article-title":"Association of IL4R single-nucleotide polymorphisms with rheumatoid nodules in African Americans with rheumatoid arthritis","volume":"12","author":"Burgos","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"R24-1-20210213","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/gene.2012.65","article-title":"MMP expression in rheumatoid inflammation: the rs11568818 polymorphism is associated with MMP-7 expression at an extra-articular site","volume":"14","author":"Kazantseva","year":"2013","journal-title":"Genes Immun"},{"key":"R25-1-20210213","first-page":"1664","article-title":"2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis","volume":"34","author":"Berkun","year":"2007","journal-title":"J Rheumatol"},{"key":"R26-1-20210213","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/138161210790112764","article-title":"Pharmacogenetics in treatment of rheumatoid arthritis","volume":"16","author":"Kooloos","year":"2010","journal-title":"Curr Pharm Des"},{"key":"R27-1-20210213","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/11531070-000000000-00000","article-title":"Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis","volume":"30","author":"Lee","year":"2010","journal-title":"Clin Drug Investig"},{"key":"R28-1-20210213","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/tpj.2011.42","article-title":"MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms","volume":"13","author":"Owen","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"R29-1-20210213","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/ng0595-111","article-title":"A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase","volume":"10","author":"Frosst","year":"1995","journal-title":"Nat Genet"},{"key":"R30-1-20210213","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1086\/301825","article-title":"A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?","volume":"62","author":"Van der Put","year":"1998","journal-title":"Am J Hum Genet"},{"key":"R31-1-20210213","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1073\/pnas.88.6.2441","article-title":"Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells","volume":"88","author":"Cronstein","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"R32-1-20210213","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","article-title":"Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis","volume":"60","author":"Cutolo","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"R33-1-20210213","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/ard.2005.048637","article-title":"Methotrexate modulates the kinetics of adenosine in humans in vivo","volume":"65","author":"Riksen","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R34-1-20210213","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/1529-0131(200003)43:3<656::AID-ANR23>3.0.CO;2-H","article-title":"Reversal of the anti-inflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis","volume":"43","author":"Montesinos","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R35-1-20210213","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/art.10712","article-title":"Adenosine A2a or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68","volume":"48","author":"Montesinos","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R36-1-20210213","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00124743-199712000-00005","article-title":"Inhibition of methotrexate-induced rheumatoid nodulosis by colchicine: evidence from an in vitro model and regression in 7 of 14 patients","volume":"3","author":"Merrill","year":"1997","journal-title":"J Clin Rheumatol"},{"key":"R37-1-20210213","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1346-8138.1999.tb02074.x","article-title":"Colchicine therapy for low-dose-methotrexate-induced accelerated nodulosis in a rheumatoid arthritis patient","volume":"26","author":"Abraham","year":"1999","journal-title":"J Dermatol"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:23:39Z","timestamp":1620951819000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201702000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000256","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}